Research & Development
Compugen receives FDA clearance of IND application for COM902 in patients with advanced malignancies
5 November 2019 -

Cancer immunotherapy company Compugen Ltd (NASDAQ:CGEN) reported on Monday the receipt of US FDA investigational new drug (IND) application for its immuno-oncology therapeutic antibody COM902 targeting TIGIT in patients with advanced malignancies.

Upon receipt of IND from the US FDA, the company plans to launch a Phase 1 clinical trial in patients with advanced malignancies for whom standard of care therapies are currently ineffective.

Expected to begin at multiple centres in the US in early 2020, the clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of COM902, according to the company.

COM902, a high affinity, fully human antibody targeting TIGIT, was developed by the company for combination treatment with COM701.

Based on preclinical data, the TIGIT inhibition, either alone or in combination with other checkpoint inhibitors, can enhance T cell activation and increase anti-tumor immune responses. Parallel inhibition of TIGIT and PVRIG results in synergistic effects on effector T cell function and tumor growth inhibition in various model systems that can be further increased with the addition of PD-1 blockade. The TIGT discovery was published by Compugen in October 2009 in the Proceedings of the National Academy of Sciences (PNAS).



Related Headlines